相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。RAB31 marks and controls an ESCRT-independent exosome pathway
Denghui Wei et al.
CELL RESEARCH (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Kari J. Kurppa et al.
CANCER CELL (2020)
Senesce to Survive: YAP-Mediated Dormancy Escapes EGFR/MEK Inhibition
Igor Bado et al.
CANCER CELL (2020)
NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma
Kang-Shuai Li et al.
CELL DEATH & DISEASE (2020)
SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer
Lin Tang et al.
ONCOGENESIS (2020)
Heterotypic cell-cell communication regulates glandular stem cell multipotency
Alessia Centonze et al.
NATURE (2020)
GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GABA-independent manner
Shu-Heng Jiang et al.
GUT (2019)
MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance
Sander P. J. Joosten et al.
GASTROENTEROLOGY (2019)
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Jordi Bertran-Alamillo et al.
NATURE COMMUNICATIONS (2019)
MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis
Yoo-Seung Ko et al.
ONCOGENE (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling
Minhong Shen et al.
CANCER CELL (2019)
Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties
Jiahui Si et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis
Galileo A. Gonzalez-Conchas et al.
CANCER TREATMENT REVIEWS (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest
Giulia Diluvio et al.
ONCOGENESIS (2018)
Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity
Christopher Dravis et al.
CANCER CELL (2018)
Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis
Lin He et al.
CELL RESEARCH (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer
Sara Duhachek-Muggy et al.
MOLECULAR CANCER (2017)
A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer
Paul Savage et al.
CELL REPORTS (2017)
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Darshan S. Chandrashekar et al.
NEOPLASIA (2017)
Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity
Bin Bao et al.
SCIENTIFIC REPORTS (2017)
EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas
Kai Zhao et al.
CANCER LETTERS (2017)
EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics
Daniel M. Freed et al.
CELL (2017)
Aberrant epigenetic regulation of GABRP associates with aggressive phenotype of ovarian cancer
Hye Youn Sung et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Shom Goel et al.
CANCER CELL (2016)
Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Linda S. Steelman et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Kindlin-2 interacts with and stabilizes EGFR and is required for EGF-induced breast cancer cell migration
Baohui Guo et al.
CANCER LETTERS (2015)
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance
Mark D. Gurden et al.
CANCER RESEARCH (2015)
The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors
Marco Treven et al.
EPILEPSIA (2015)
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity
Bruno M. Simoes et al.
CELL REPORTS (2015)
The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells
Antonia Bellizzi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
The Epidermal Growth Factor Receptor (EGFR/HER-1) Gatekeeper Mutation T790M Is Present in European Patients with Early Breast Cancer
Vahid Bemanian et al.
PLOS ONE (2015)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
GABA(A) Receptor Pi (GABRP) Stimulates Basal-like Breast Cancer Cell Migration through Activation of Extracellular-regulated Kinase 1/2 (ERK1/2)
Gina M. Sizemore et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling
Rumela Chalcrabarti et al.
NATURE CELL BIOLOGY (2014)
被撤回的出版物: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells (Retracted article. See vol. 119, 2022)
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors
Rainelli B. Koumangoye et al.
MOLECULAR CANCER (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Min Yu et al.
SCIENCE (2013)
Endocytosis of Receptor Tyrosine Kinases
Lai Kuan Goh et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer
Pascal Jezequel et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
L. Malorni et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
Mogens Bernsdorf et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Lipid Raft Localization of EGFR Alters the Response of Cancer Cells to the EGFR Tyrosine Kinase Inhibitor Gefitinib
Mary E. Irwin et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Intratumoral Expression Level of Epidermal Growth Factor Receptor and Cytokeratin 5/6 Is Significantly Associated With Nodal and Distant Metastases in Patients With Basal-like Triple-Negative Breast Carcinoma
Lisa M. Sutton et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
Alfonso Sanchez-Munoz et al.
BMC CANCER (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
Triple-negative breast cancer-current status and future directions
O. Gluz et al.
ANNALS OF ONCOLOGY (2009)
Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance
Jonna Nevo et al.
CLINICAL CANCER RESEARCH (2009)
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
Xiaoxian Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells
Jillian Howlin et al.
BREAST CANCER RESEARCH (2008)
A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
Sheri K. Dennison et al.
INVESTIGATIONAL NEW DRUGS (2007)
γ-Aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor π subunit
Akio Takehara et al.
CANCER RESEARCH (2007)
Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy
Dianne S. Hirsch et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting
Maria L. Jaramillo et al.
EXPERIMENTAL CELL RESEARCH (2006)
Overview of tyrosine kinase inhibitors in clinical breast cancer
A Agrawal et al.
ENDOCRINE-RELATED CANCER (2005)
Notch in mammary gland development and breast cancer
K Politi et al.
SEMINARS IN CANCER BIOLOGY (2004)
Is there more to GABA than synaptic inhibition?
DF Owens et al.
NATURE REVIEWS NEUROSCIENCE (2002)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
A neurochemical study of the novel antiepileptic drug retigabine in mouse brain
GJ Sills et al.
PHARMACOLOGICAL RESEARCH (2000)
分享论文
